DGAP-News: Epicore BioNetworks Inc. Reports Results for Fiscal Year 2013
(firmenpresse) - Epicore BioNetworks Inc.
10.10.2013 22:35
---------------------------------------------------------------------------
EASTAMPTON, N.J., 2013-10-10 22:35 CEST (GLOBE NEWSWIRE) --
Epicore (TSX-V:EBN) was able to maintain its fiscal 2013 sales revenues at
fiscal 2012 level despite a difficult year for the shrimp aquaculture industry.
Quarter four sales outperformed the first three months of the year and set a
Company record. Fiscal 2013 gross profit increased 3% due to sales mix. Cash
generation was strong in the year (19% above fiscal 2012) and shareholder
equity increased 12% to $5.4 million. Fiscal 2013 saw a major investment in
manufacturing resources, which will have a favorable effect on future
operations but contributed to a 27% drop in fiscal 2013 net income.
Consumer demand for shrimp remained high throughout fiscal 2013 although high
prices caused import drops in several major markets. Severe supply shortages
due to disease pushed up shrimp prices to record levels. High shrimp prices
create a favorable atmosphere for Epicore's productivity improving products but
farm closures due to disease hurt Epicore sales, even more than they did in
fiscal 2012. The Epicore sales team and our distributors responded to this
challenge by securing new customers, opening new market areas and exploiting
new applications for Epicore products.
Epicore completed its major initiative to improve its science and manufacturing
resources, which will position the Company for significant future growth and
increase the reliability of its operations. Our ISO 9001:2008 quality system
certification also contributed to operational reliability. Some highlights (in
US$) versus prior fiscal year were:
-- No change in revenue at $5.6 million
-- Increase in gross profit from $3.4 million to $3.5 million (a 3% increase)
-- Increase in operating expenses from $2.2 to $2.7 million (a 21% increase)
-- Decrease in net income from $0.7 million to $0.5 million (a 27% decrease)
-- Decrease in EBITDA from $1.2 million to $0.9 million (a 28% decrease)
-- Increase in shareholders' equity from $4.8 million to $5.4 million (a 12%
increase)
-- Increase in cash from $1.6 million to $1.9 million (a 19% increase)
-- Decrease in basic and diluted earnings per share from $0.03 to $0.02
Gross profit grew 3% due to an improvement in gross margin that was mainly due
to product mix. Operational expenses increased by 21% in fiscal 2013 due to
increased selling effort, inflation and spending on our strategic initiative. A
cornerstone of the initiative was new production equipment that was installed
in fiscal 2013 but was in a commissioning mode and not in a production mode for
most of the fiscal year. Research and development expenses increased 5% because
of higher outside research effort. With the research and development strategy
in place and the production resources that were added, management expects to
continue to improve the quality and reliability of its manufacturing operations
and to accelerate the Company's reach and penetration into new business areas.
Epicore generated positive net income of $0.5 million to give Epicore its tenth
consecutive year of profitable operation. Versus prior year, net income
decreased by $0.2 million (27%). EBITDA (earnings before interest, taxes,
depreciation and amortization) decreased 28% over prior year from $1.2 million
to $0.9million, as the following results show:
------------------------------------------------------------------
2013 2012 Increase (Decrease)
-----------------------------------------------------------------
Revenue $5,613,100 $5,635,700 ($22,600) 0%
-----------------------------------------------------------------
Gross profit $3,545,500 $3,429,000 $116,500 3%
-----------------------------------------------------------------
Operating expenses $2,702,400 $2,229,000 $473,400 21%
-----------------------------------------------------------------
Net income $482,200 $659,900 ($177,700) (27%)
-----------------------------------------------------------------
Earnings per share $0.02 $0.03 ($0.01) (32%)
-----------------------------------------------------------------
Shareholders' equity $5,431,600 $4,849,800 $581,800 12%
-----------------------------------------------------------------
Cash balance $1,938,800 $1,628,300 $310,500 19%
-----------------------------------------------------------------
Epicore continues to generate positive cash flows from operating activities
with $0.7 million generated in fiscal 2013, which was $0.2 million less than
fiscal 2012. Cash at the end of the year was $1.9 million. With these funds,
expected sales revenue growth and continued relatively low operating costs,
management expects there will be sufficient cash to meet the fiscal year's
financial requirements, to fund expansion of aquaculture and environmental
remediation marketing efforts and to pursue new strategies for enhancing
shareholder value.
Fiscal 2013 was a successful year not only on a financial basis, but it saw
major progress on several operational and strategic issues. The Company
actively worked to maintain its ISO 9001:2008 certification and began a program
to get HACCP (hazard analysis and critical control point) and Global GAP
certification. Many shrimp processing companies have one or more international
certifications. Additionally, many government aquaculture product registration
authorities are looking for some type of quality certification.
Fiscal 2013 also saw progress on several corporate issues.
-- To strengthen its Board of Directors, the Company added a fifth member.
-- Also in the year, Epicore met the requirements for and was granted Tier One
status by the TSX Venture Exchange. This move up from Tier Two status
reflects the evolving maturity of Epicore's business.
-- Epicore was recognized as the New Jersey member of the year by the World
Trade Center of Greater Philadelphia at the WTCGP annual dinner. The WTCGP
has provided Epicore export advice and opened doors for Epicore in China.
The financial statements of the company have been prepared in accordance with
International Financial Reporting Standards. Epicore BioNetworks Inc. is a
public corporation with a registered office in Calgary, Alberta, Canada and
with shares listed on the TSX Venture Exchange (symbol EBN). [Neither TSX
Venture Exchange nor its Regulation Services Provider (as that term is defined
in the policies of the TSX Venture Exchange) accepts responsibility for the
adequacy or accuracy of this release.]
This press release contains forward-looking statements that involve significant
risks and uncertainties. The actual results, performance or achievements of the
company might differ materially from the results, performance or achievements
of the company expressed or implied by such forward-looking statements. Such
forward-looking statements include, without limitation, those regarding the
future growth of the Company, expected improvements in the quality and
reliability of manufacturing operations, acceleration of the Company's
penetration into new business areas, the development plans of the company, the
expected timing and results of such development and the expectation by
management that there will be sufficient cash to meet the fiscal year's
financial requirements. We can provide no assurance that such development will
proceed as currently anticipated, that the expected timing or results of such
development will be realized or that the company will be able to generate
sufficient cash to meet its obligations. We are subject to various risks,
including the uncertainties of product development, markets for our products
and regulatory review, our need for additional capital to fund our operations,
our reliance on collaborative partners, our history of losses, and other risks
inherent in the biotechnology industry.
Mr. William P. Long (Chief Executive Officer) USA
Tel: 609-267-9118
Email: Investors(at)EpicoreBioNetworks.com
News Source: NASDAQ OMX
10.10.2013 Dissemination of a Corporate News, transmitted by DGAP -
a company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Epicore BioNetworks Inc.
United States
Phone:
Fax:
E-mail:
Internet:
WKN:
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 10.10.2013 - 22:35 Uhr
Sprache: Deutsch
News-ID 304939
Anzahl Zeichen: 0
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 236 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Epicore BioNetworks Inc. Reports Results for Fiscal Year 2013"
steht unter der journalistisch-redaktionellen Verantwortung von
Epicore BioNetworks Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
